Status:
COMPLETED
Adductor Canal Block Versus Liposomal Bupivacaine in TKA
Lead Sponsor:
Good Samaritan Regional Medical Center, Oregon
Conditions:
Total Knee Arthroplasty
Post-operative Pain Control
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This is a randomized prospective study of 60 patients undergoing total knee arthroplasty evaluating the clinical outcomes of liposomal bupivacaine periarticular injections (PAI) when compared to singl...
Detailed Description
Total knee arthroplasty(TKA) is an effective solution for end stage arthritis of the knee; however, post-surgical pain can be difficult to manage and the optimal peri-operative pain management strateg...
Eligibility Criteria
Inclusion
- Patients undergoing unilateral primary total knee arthroplasty for end stage osteoarthritis or rheumatoid arthritis.
- All adults \> 18 years of age.
Exclusion
- Not cleared by PCP and appropriate specialists to undergo TKA (Check No if patient has been cleared.)
- Adults undergoing bilateral primary total knee arthroplasties.
- Women who are pregnant.
- Women who are breastfeeding.
- Inability to receive successful spinal anesthesia.
- Allergy to amide anesthetics.
- Inability to receive IV tranexamic acid.
- Patients who are unable to speak English.
- Patients who are less than 66kg.
- Patients who are opioid dependent. We define opioid dependency as patients who are on a long-acting narcotic or patients who are taking more than six tablets of hydrocodone 5mg or equivalent.
Key Trial Info
Start Date :
March 22 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 18 2018
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04086186
Start Date
March 22 2017
End Date
December 18 2018
Last Update
September 11 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Good Samaritan Regional Medical Center
Corvallis, Oregon, United States, 97330